Trade Chinook Therapeutics, Inc. - KDNY CFD

Add to favourite

40.34

0.2%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.11

Long position overnight fee

-0.024151%

Short position overnight fee

0.001929%

Overnight fee time

22:00 (UTC)

Min traded quantity

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	40.26
Open	40.28
1-Year Change	107.42%
Day's Range	40.24 - 40.35

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Aug 10, 2023	40.34	0.09	0.22%	40.25	40.45	40.24
Aug 9, 2023	40.26	0.03	0.07%	40.23	40.27	40.22
Aug 8, 2023	40.27	0.04	0.10%	40.23	40.32	40.23
Aug 7, 2023	40.27	0.06	0.15%	40.21	40.33	40.20
Aug 4, 2023	40.23	0.02	0.05%	40.21	40.24	40.20
Aug 3, 2023	40.24	0.09	0.22%	40.15	40.25	40.15
Aug 2, 2023	40.14	-0.10	-0.25%	40.24	40.27	40.07
Aug 1, 2023	40.24	-0.01	-0.02%	40.25	40.41	40.21
Jul 31, 2023	39.12	0.13	0.33%	38.99	39.22	38.90
Jul 28, 2023	39.02	0.07	0.18%	38.95	39.05	38.90
Jul 27, 2023	38.89	-0.15	-0.38%	39.04	39.10	38.84
Jul 26, 2023	39.03	-0.01	-0.03%	39.04	39.07	38.86
Jul 25, 2023	39.03	-0.07	-0.18%	39.10	39.18	39.01
Jul 24, 2023	39.19	0.31	0.80%	38.88	39.31	38.86
Jul 21, 2023	38.84	-0.20	-0.51%	39.04	39.20	38.81
Jul 20, 2023	39.04	-0.12	-0.31%	39.16	39.27	38.95
Jul 19, 2023	39.15	-0.16	-0.41%	39.31	39.39	39.13
Jul 18, 2023	39.29	-0.04	-0.10%	39.33	39.48	39.28
Jul 17, 2023	39.33	0.17	0.43%	39.16	39.35	39.12
Jul 14, 2023	39.18	0.08	0.20%	39.10	39.19	39.02

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Chinook Therapeutics, Inc. Company profile

About Chinook Therapeutics Inc

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing precision medicines for kidney diseases. The Company's development programs consist of Atrasentan, BION-1301 and CHK-336. Atrasentan is a potent and selective endothelin A receptor antagonist that are developed for the treatment of proteinuric glomerular diseases. BION-1301 is an investigational humanized IgG4 monoclonal antibody that blocks APRIL binding to both the B-cell maturation antigen (BCMA), and transmembrane activator and CAML interactor (TACI), receptors, as a disease-modifying therapy for Immunoglobulin A Nephropathy (IgAN). CHK-336 is a liver-targeted oral small molecule lactate dehydrogenase (LDHA), inhibitor, which are developed for the treatment of primary hyperoxaluria.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Chinook Therapeutics Inc revenues increased from $827K to $51.6M. Net loss increased 26% to $102.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development-other increase from $24.8M to $66.1M (expense), Change in fair value of contingent consi increase from $1.5M to $27.3M (expense).

Industry:

Bio Therapeutic Drugs

400 Fairview Avenue North, Suite 900
SEATTLE
WASHINGTON 98109
US

News

Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target

Can Shiba Inu reinvent itself to become a worthy long-term investment?

08:36, 15 November 2024

Trump trades charge as Bitcoin hits $US80,000

Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.

10:48, 13 November 2024

Australian jobs data expected to point to solid labour market conditions

Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.

10:16, 13 November 2024

FOMC cuts interest rates as expected and sticks to its line on future policy

The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.

13:33, 8 November 2024

FOMC and BOE preview: further rate cuts expected

Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.

14:14, 5 November 2024

RBA meeting preview: No change to policy expected as inflation fight continues

The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.

13:35, 4 November 2024